首页> 美国卫生研究院文献>Clinical and Developmental Immunology >Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus
【2h】

Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus

机译:免疫信息学方法用于基于表位的肽疫苗设计和针对新兴奥罗波奇病毒多蛋白的活性位点预测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oropouche virus (OROV) is an emerging pathogen which causes Oropouche fever and meningitis in humans. Several outbreaks of OROV in South America, especially in Brazil, have changed its status as an emerging disease, but no vaccine or specific drug target is available yet. Our approach was to identify the epitope-based vaccine candidates as well as the ligand-binding pockets through the use of immunoinformatics. In this report, we identified both T-cell and B-cell epitopes of the most antigenic OROV polyprotein with the potential to induce both humoral and cell-mediated immunity. Eighteen highly antigenic and immunogenic CD8+ T-cell epitopes were identified, including three 100% conserved epitopes (TSSWGCEEY, CSMCGLIHY, and LAIDTGCLY) as the potential vaccine candidates. The selected epitopes showed 95.77% coverage for the mixed Brazilian population. The docking simulation ensured the binding interaction with high affinity. A total of five highly conserved and nontoxic linear B-cell epitopes “NQKIDLSQL,” “HPLSTSQIGDRC,” “SHCNLEFTAITADKIMSL,” “PEKIPAKEGWLTFSKEHTSSW,” and “HHYKPTKNLPHVVPRYH” were selected as potential vaccine candidates. The predicted eight conformational B-cell epitopes represent the accessibility for the entered virus. In the posttherapeutic strategy, ten ligand-binding pockets were identified for effective inhibitor design against emerging OROV infection. Collectively, this research provides novel candidates for epitope-based peptide vaccine design against OROV.
机译:Oropouche病毒(OROV)是一种新兴病原体,可导致人的Oropouche发烧和脑膜炎。在南美,特别是在巴西,几次OROV暴发改变了其作为新兴疾病的地位,但尚无疫苗或特定的药物靶标。我们的方法是通过使用免疫信息学来鉴定基于表位的候选疫苗以及配体结合口袋。在这份报告中,我们确定了最具抗原性的OROV多蛋白的T细胞和B细胞表位,具有诱导体液和细胞介导的免疫力的潜力。鉴定出十八种高度抗原性和免疫原性的CD8 + T细胞表位,包括三个100%保守的表位(TSSWGCEEY,CSMCGLIHY和LAIDTGCLY)作为潜在的候选疫苗。选定的表位显示混合巴西人口的95.77%覆盖率。对接模拟确保了高亲和力的结合相互作用。总共选择了五个高度保守且无毒的线性B细胞表位“ NQKIDLSQL”,“ HPLSTSQIGDGDRC”,“ SHCNLEFTAITADKIMSL”,“ PEKIPAKEGWLTFSKEHTSSW”和“ HHYKPTKNLPHVVPRYH”。预测的八个构象B细胞表位代表进入病毒的可及性。在治疗后策略中,确定了十个配体结合口袋,可有效设计针对新兴OROV感染的抑制剂。总之,这项研究为针对OROV的基于表位的肽疫苗设计提供了新的候选对象。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号